The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments: A multicenter retrospective real-world study.
 
Weihong Ma
No Relationships to Disclose
 
Jiamin Cheng
No Relationships to Disclose
 
Hongli Yu
No Relationships to Disclose
 
Caiyun Peng
No Relationships to Disclose
 
Jie Han
No Relationships to Disclose
 
Jiaqi Liu
No Relationships to Disclose
 
Zhipeng Liang
No Relationships to Disclose
 
Qinghao Kong
No Relationships to Disclose
 
Wenjing Wang
No Relationships to Disclose
 
Jinghui Dong
No Relationships to Disclose
 
Aiying Jia
No Relationships to Disclose
 
Yinying Lu
No Relationships to Disclose